GlassScriptPhysician profile
Abimbola Ogunleye
NPI 1023294261
$3,579.06
in general payments reported to CMS, 2019-2025
25 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.00 · 2022: $165 · 2023: $359 · 2024: $1,300 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $637.15 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $464.71 | 2024-2025 | |
| Novo Nordisk INC | $438.43 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $397.04 | 2021-2025 | |
| Lilly USA, LLC | $298.24 | 2023-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.67 | 2025 | Caplyta |
| Shield Therapeutics INC | $232.96 | 2023-2025 | Accrufer |
| Amgen INC. | $134.89 | 2025 | Krystexxa, Repatha, Otezla |
| Abiomed | $104.22 | 2024 | Impella |
| Daiichi Sankyo INC. | $103.43 | 2022-2024 | Injectafer |
| Hologic Sales and Service, LLC | $77.88 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Paratek Pharmaceuticals, INC. | $58.23 | 2022-2023 | Nuzyra |
| Ultragenyx Pharmaceutical INC. | $55.98 | 2022 | |
| Glaxosmithkline, LLC. | $51.27 | 2025 | Trelegy Ellipta |
| Medtronic, INC. | $44.34 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.90 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $31.46 | 2025 | |
| Photonicare INC | $27.23 | 2025 | Otosight Middle Ear Scope |
| Agios Pharmaceuticals, INC. | $22.67 | 2025 | Pyrukynd |
| Agepha Pharma Fz LLC | $21.22 | 2025 | Lodoco |
| Phathom Pharmaceuticals, INC. | $18.63 | 2025 | Voquezna |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $18.51 | 2022 | |
| Abbott Laboratories | $17.90 | 2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.39 | 2025 | Xifaxan |
| Philips North America LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abimbola Ogunleye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.